galantamine has been researched along with Parkinsonian Disorders in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kishimoto, K; Kitamura, Y; Minamino, H; Shibaike, T; Shimohama, S; Takata, K; Takeuchi, H; Taniguchi, T; Tsushima, J; Yanagida, T; Yasui, H | 1 |
Abbas, SF; Baqi, Y; Chrobak, JJ; Collins, LE; Galtieri, DJ; Leser, CE; Müller, CE; Paul, NE; Podurgiel, SJ; Salamone, JD | 1 |
Edwards, K; Farlow, M; Hake, A; Hershey, L; Johnson, S; Lichter, D; Pasquier, F; Royall, D | 1 |
1 trial(s) available for galantamine and Parkinsonian Disorders
Article | Year |
---|---|
Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study.
Topics: Aged; Aged, 80 and over; Behavioral Symptoms; Cholinesterase Inhibitors; Dementia; Dose-Response Relationship, Drug; Female; Galantamine; Hallucinations; Humans; Lewy Body Disease; Male; Mental Status Schedule; Middle Aged; Neurologic Examination; Neuropsychological Tests; Parkinsonian Disorders; Treatment Outcome | 2007 |
2 other study(ies) available for galantamine and Parkinsonian Disorders
Article | Year |
---|---|
Synergistic effect of galantamine on nicotine-induced neuroprotection in hemiparkinsonian rat model.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Disease Models, Animal; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Synergism; Electron Spin Resonance Spectroscopy; Functional Laterality; Galantamine; Gene Expression Regulation; Male; Mecamylamine; Methamphetamine; Motor Activity; Neuroprotective Agents; Nicotine; Nicotinic Antagonists; Parkinsonian Disorders; Rats; Rats, Wistar; Receptors, Nicotinic; RNA, Messenger; Rotarod Performance Test; Tyrosine 3-Monooxygenase | 2008 |
Oral tremor induced by galantamine in rats: a model of the parkinsonian side effects of cholinomimetics used to treat Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cholinergic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Electromyography; Galantamine; Jaw; Male; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Treatment Outcome; Tremor | 2011 |